Eurofins Scientific SE · EURONEXT:ERF

Eurofins Scientific — Investor Day (October 2023)

60 slides from Eurofins Scientific's investor day presentation, Oct 25, 2023

  1. Slide 1: 2023 European Investor Day

    CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af

  2. Slide 2: Disclaimer

    Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on

  3. Slide 3: Eurofins: The World Leader in Testing for Life

    Eurofins: The World Leader in Testing for Life Key Figures 36 years of value creation • Long-term track record of turning investments into growth, productivity, margin expansion and Return on Capital Employed ca. 900 laboratories 450,000,000+ • Competitive advantages based on tests performed each ye

  4. Slide 4: Eurofins remains very confident in its objectives for organic growth and M&A

    Eurofins remains very confident in its objectives for organic growth and M&A Revenue bridge (2023E to 2027E) Approaching organic M&A €10bn growth organic M&A growth organic M&A growth €6.45bn organic M&A to growth €6.55bn • Continued strong growth outlook in all Eurofins activities average • Increas

  5. Slide 5: Continued strong secular growth outlook in all Eurofins activities

    Continued strong secular growth outlook in all Eurofins activities 2023-2027 objective: 6.5% p.a. average organic growth Revenue share Organic growth Activities in H1 2023 Growth drivers outlook • Rising awareness and demand for food safety & quality • Food and Feed Testing and contamination & pollu

  6. Slide 6: Solid margin performances in North America and Rest of the World

    Solid margin performances in North America and Rest of the World, while improvement needed in Europe due to disruptions following the war in Ukraine Europe North America Rest of the World 40% 40% 40% COVID revenue peak COVID revenue peak COVID revenue peak 30% 30% 30% 20% 20% 20% 10% 10% 10% 0% 0% 0

  7. Slide 7: Eurofins is developing proprietary automation technologies

    Eurofins is developing proprietary automation technologies and starting to deploy them across its global network Bespoke modular automation platform Attractive financial profile Multi-year investments underway • Significant OpEx for development • Part of CapEx for growth and efficiency Example Conta

  8. Slide 8: Eurofins' proprietary IT solution offers more for clients and costs less

    Eurofins’ proprietary IT solution offers more for clients and costs less than externally available software (example BioPharma Product Testing solutions suite) Eurofins’ proprietary BPT solution Benefits of Eurofins bespoke proprietary IT solutions Advantage: Differentiation and standardisation acro

  9. Slide 9: Disciplined capital allocation has been the foundation of profitable expansion

    Disciplined capital allocation has been the foundation of the profitable expansion of Eurofins Core Business1 12 1 Core Business Revenue (€bn) 10 8 COVID-19 Revenue (€bn) 0.6 6 1.4 0.8 Approaching 10 4 6.45 €10bn 6.1 to 4.6 4.6 5.3 6.55 2 3.0 3.8 2.0 2.5 0 1.0 1.2 1.4 2 2012 2013 2014 2015 2016 2017

  10. Slide 10: Prudent capital allocation strategy centred on growth investments

    Eurofins remains committed to its prudent capital allocation strategy centred on growth investments1 Cash flow generation (2019-2022) Investment allocation 2019-2022 (2019-2022) % of sales Maintenance capex Assume ~2.5% of sales Sales €23.4bn Net cash provided by operating activities €4.5bn 19.4% Ac

  11. Slide 11: Investments in start-ups are integral to long-term growth

    Investments in start-ups are integral to long-term growth and value creation Long track record Strategic rationale Contributions by start-ups in FY 2022 Number of start-ups created Complements M&A strategy: • When acquisitions are too expensive or Organic growth contribution Programme Total Per year

  12. Slide 12: Site ownership has attractive financial fundamentals

    Site ownership has attractive financial fundamentals Benefits Examples • Estimated rent savings of €68m1 in FY 2022 from owned sites 1 Savings • Estimated yield on rent savings from owned sites of 11% (based on net book value at end of 2022 of €635m) • Lower operating costs from investment in renewa

  13. Slide 13: Very healthy leverage and long-term debt maturity profile

    Very healthy leverage and long-term debt maturity profile Leverage1 Debt maturity profile at 30 June 20233 (€m) Key Highlights Including effect of Eurobond issued in September 2023 • Net debt decreased from €3,245 at the end of FY 2019 to €2,588m2 at 3.2x Cash the end H1 2023 Hybrid (1st call) • 90%

  14. Slide 14: Our mid-term objectives & drivers

    Our mid-term objectives & drivers (€m) FY 2023 Mid-term objectives & drivers FY 2027 • Average +6.5% organic growth p.a. Revenues €6.45bn – €6.55bn • Potential average revenues from acquisitions of €250m p.a. Approaching €10bn • Organic growth and acquisitions • Align pricing to cost inflation Adj.

  15. Slide 15: Summary

    Summary Continued strong secular growth outlook in all Eurofins activities Long-term track record of disciplined capital allocation to drive growth, productivity, margin expansion and Return on Capital Employed Market leadership Ongoing investment to develop and deploy sector-leading proprietary IT

  16. Slide 16: Food & Feed Testing European Network

    CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af

  17. Slide 17: Eurofins operates the best-in-class Food & Feed Testing network in Europe

    Eurofins operates the best-in-class Food & Feed Testing network in Europe Eurofins Food and Feed Testing European Network Market leader in significant markets • Nordics • Spain • Germany • Benelux • France • UK & Ireland >100 laboratories throughout Europe, including 5 hubs offering specialised test

  18. Slide 18: Addressable global food & feed testing market enjoys robust growth drivers

    Eurofins’ >$4bn1 addressable global food & feed testing market enjoys robust growth drivers Globalisation: raw Consumers’ Outsourcing of Food scares and materials sourced increasing awareness industry’s internal or crises, widely covered from countries with and demand for safe state- owned in the me

  19. Slide 19: Food & Feed Testing offering is the most comprehensive in the market

    Eurofins’ Food & Feed Testing offering is the most comprehensive in the market Agricultural production, Production Retail and distribution product development Microbiology Sensorial Veterinary Quality Dioxins Vitamins drug residues Control Authenticity Organic Pesticides POPs Labelling GMO residues

  20. Slide 20: Our leading Food & Feed Testing market position

    Our leading Food & Feed Testing market position is underpinned by the trust of our customers Food & beverage Agriculture Retailers Restaurants & Caterers producers Customers1 & Contracts Global players International conglomerates Supermarket chains Major operators Caterers + regional & local markets

  21. Slide 21: Why customers choose Eurofins

    Why customers choose Eurofins Leading expertise One-stop-shop Customer service • Comprehensive portfolio of state-of-the-art • We test almost all types of products that are • Fast and swift local service - in the laboratory and analytical techniques, always up to date with consumed or used in food &

  22. Slide 22: Food & Feed Testing offers pricing and automation opportunities

    Eurofins’ Food & Feed Testing offers pricing and automation opportunities Broad • Pricing: breadth of Cost Leadership Differentiation portfolio and niche Service Offering testing • Automation: low cost/high volume testing Narrow Cost Focus Differentiation Focus Cost Differentiation Operating Model 2

  23. Slide 23: Improved systems and processes to improve pricing

    Improved systems and processes to improve pricing Systems Opportunities Indexation • Harmonisation of IT systems • Analysis of data to identify • Price increase indexation opportunities based on each targets set at business unit • Able to measure, monitor and client’s: level to match cost increases

  24. Slide 24: Automation opportunities across Food & Feed laboratories

    Automation opportunities across a large range of processes within Food & Feed laboratories Pesticide laboratories FTEs split by process 15% Laboratory Processes Customer Service Processes • Operations steps: sample preparation and distribution, preparation of analysis, analysis • Operations steps: q

  25. Slide 25: Our leading IT infrastructure is the basis of the laboratory of the future

    Our leading IT infrastructure is the basis of automating the laboratory of the future Fully-automated food & feed sample preparation system Competitive advantages • Benefits of automation: • Reduction in operating costs • Continuous flow / one piece flow • Overnight sample processing • Complete trac

  26. Slide 26: Summary

    Summary Operate best-in-class Food & Feed Testing network in Europe Most comprehensive offering Market Leading market position leadership Testing provider of choice by our customers Sustainable competitive advantages, including IT leadership 26

  27. Slide 27: Environment Testing European Network

    CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af

  28. Slide 28: Eurofins operates the best-in-class Environment Testing network in Europe

    Eurofins operates the best-in-class Environment Testing network in Europe Eurofins Environment Testing European Network Market leader in significant markets • Nordics • Spain • Germany • Belgium • France • The Netherlands • Austria • Ireland >110 laboratories throughout Europe, including >10 hubs of

  29. Slide 29: Addressable global environment testing market enjoys robust growth drivers

    Eurofins’ >$5bn1 addressable global environment testing market enjoys robust growth drivers Progress in epidemiology & Rise in contamination & Increasing demand by citizens medicine has identified more pollution issues for a clean environment compounds as toxic Increasingly long list of products ide

  30. Slide 30: Environment Testing offering is the most comprehensive in the market

    Eurofins’ Environment Testing offering is the most comprehensive in the market Water Soil Air Other ▪ Drinking water, waste waters, ▪ Biofuels groundwater analysis ▪ Analysis of soil for full range of ▪ Outdoor pollutants ▪ Building materials ▪ Full range of contaminants contaminants ▪ Indoor and am

  31. Slide 31: Our leading Environment Testing market position

    Our leading Environment Testing market position is underpinned by the trust of our customers Engineering, Consulting, Industry, Manufacturing & Soil & Hazardous Waste Governments, Universities Construction firms firms & Non-Profits Customers1 & Contracts Global players Global players Typical service

  32. Slide 32: Scaling our proven in-house AI innovations

    Scaling our proven in-house AI innovations to address new applications of testing in our laboratories Industrialised an accredited visual AI1 detection Further AI development to detect Leverage the same AI method for other method on TEM2 microscopes even more contaminants applications Asbestos on TE

  33. Slide 33: Case study: automation projects at Eurofins Analytico, Barneveld

    Case study: leveraging scale to lead valuable automation projects at Eurofins Analytico, Barneveld Location Employees Facility Samples processed Barneveld, NL 430 FTEs 8,300 m² 632,000 in 2022 Mapping the process workflow of the laboratory Business case evaluation Outcomes Define business cases for

  34. Slide 34: Recent studies highlight expanding PFAS challenge and testing market

    Recent studies highlight expanding PFAS challenge and testing market opportunity PFAS contamination in Europe1 Regulations to drive PFAS testing demand • >17,000 sites where PFAS contamination has been detected • Additional >21,000 presumptive PFAS contamination sites • Jan 2023: European Commission

  35. Slide 35: Eurofins is a technology and thought leader in PFAS testing

    Eurofins is a technology and thought leader in PFAS testing Science behind PFAS testing increasing in scope and complexity Eurofins industry leadership Eurofins was the first commercial Laboratory Group to conduct Non-Targeted PFAS analysis OECD • Looking for complete unknowns allows us to revised i

  36. Slide 36: Extensive geographical and technological coverage for PFAS testing

    Eurofins has one of the most extensive geographical and technological coverages for PFAS testing Leading global laboratory network for PFAS testing PFAS testing capabilities by medium Water • Monitoring drinking water programmes in the U.S., France and Scandinavia Specialist PFAS laboratories in • L

  37. Slide 37: Summary

    Summary Operate best-in-class Environment Testing network in Europe Most comprehensive offering Market Leading market position leadership Testing provider of choice by our customers Sustainable competitive advantages, including IT leadership 37

  38. Slide 38: BioPharma Services

    CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af

  39. Slide 39: BioPharma Services – Comprehensive Global Offering

    BioPharma Services – Comprehensive Global Offering Clinical Development Pre-clinical / BioPharma PSS1 (Central & Agroscience Genomics Discovery Early Product Insourcing Laboratory/ Manufacturing Services Development Testing Solutions Bioanalytical) (CDMO) 20 countries US 40 sites 287 projects US US

  40. Slide 40: Leading Global BioPharma Network

    Leading Global BioPharma Network ~190,000 m2 Leader in significant markets ~130,000 ~5,000 • Global leader in BioPharma Product Testing m2 ~6,000 employees employees • Global leader in Discovery Pharmacology Services 82 • Global leader in Agroscience CRO Services laboratories 32 Europe laboratories

  41. Slide 41: BioPharma Services Evolution

    BioPharma Services Evolution Started Select milestones / acquisitions Market position today 2011: Global infrastructure established (US, Among top 5 global players 2001 Central Laboratory / Bioanalytical Acquisitions: Netherlands, Singapore, China, India) 2005 Genomic Services Acquisitions: Among to

  42. Slide 42: Clients & Peers

    Clients & Peers Major Biopharma companies Innovative biotech Example clients Clients1 + regional & local players Typical contractual ➢ Product Testing: annual master service agreements relationship: ➢ Research & Development Services: project-based agreements Peers + regional & local competitors 1 Ex

  43. Slide 43: Market Update

    Market Update 43

  44. Slide 44: State of BioPharma Industry Funding

    State of BioPharma Industry Funding BioPharma Funding ($bn) BioPharma Firepower ($bn) (IPOs, Follow-ons, Private and Public/Other) • Biotech funding has normalised in 2022-2023E at levels on par with best 1,422 135 118 levels pre-COVID, as investor willingness to fund promising 68 67 candidates rema

  45. Slide 45: R&D Spend Evolution

    R&D Spend Evolution Worldwide Total Pharmaceutical R&D Spend ($bn)1 Market drivers R&D spend continues to grow substantially, driven by 350 intensity & speed of innovation 289 296 302 • Increased focus on biologics vs. small molecules 300 281 262 272 = increasing amounts spent per drug 249 250 244 •

  46. Slide 46: Large Market Opportunities

    Large Market Opportunities Novel innovations1 Chemicals Biologics Cell and gene therapies Opportunities for Eurofins Description / Increasing complexity in Complexity2 testing and clinical trials Altering of genetic material Increased likelihood of outsourcing of testing Traditional, biomarkers, Tra

  47. Slide 47: Delivering Value to our Clients

    Delivering Value to our Clients 47

  48. Slide 48: Strategic expansion of the BioPharma network

    Strategic expansion of the BioPharma network Expanding capacity across our areas of activity Net floor area (k m2) for BioPharma BioPharma Discovery Genomic CDMO Services Change Product Testing Services Services 400 2018-2022 Dungarvan, IE 350 • Significant Glostrup, DK Homburg, DE investments in fi

  49. Slide 49: DiscoveryOne: Enabling Drug Discovery Through Integration

    DiscoveryOne™ Enabling Drug Discovery Through the Integration of Our Comprehensive Global offering and Consulting Capabilities 10 Eurofins Companies Integrated service offering Strong Growth >5X revenues Acquired 2013 Biotherapeutics & Acquired 2004 Acquired 2012 Chemistry Cell/Gene Therapy Discover

  50. Slide 50: DiscoveryAI: Accelerating drug discovery through artificial intelligence

    DiscoveryAI™ Accelerating drug discovery through artificial intelligence Our unique competitive advantage DiscoveryAI potential • High-quality proprietary datasets used to train superior Machine Learning models Drug-to-market time: reduced by >20% Predictive accuracy: 75% • Sizeable dataset (2,500 c

  51. Slide 51: Established leading player in Cell and Gene Therapy

    Established leading player in Cell and Gene Therapy with comprehensive client offering and >10 years of experience Successful and long track Supported the development of: record with Cell and Gene • 16 of 24 FDA-approved1 Cell and Gene Therapy Products Therapies (C&GT) • All 6 CAR-T therapies Eurofi

  52. Slide 52: Eurofins' proprietary IT solution offers more for clients

    Eurofins’ proprietary IT solution offers more for clients and costs less than externally available software (example BioPharma Product Testing solutions suite) Eurofins’ proprietary BPT solution Benefits of Eurofins bespoke proprietary IT solutions Advantage: Differentiation and standardisation acro

  53. Slide 53: Differentiators and unique positioning

    Differentiators and unique positioning One-stop-service provider with a local, tailored approach to clients: Decentralised & Agile Innovative & R&D Driven Solutions: Specialty solutions for Biologics Customer Support larger clients across multiple countries and continents around the world trust Diff

  54. Slide 54: BioPharma Services CRO Leadership Awards

    “8 eurofins | BioPharma Services CRO _AWARD RECIPIENT mous 11TH CONSECUTIVE YEAR CRO CRO CRO LEADERSHIP LEADERSHIP LEADERSHIP AWARDS2023 AWARDS2023 AWARDS202> EXPERTISE QUALITY CAPABILITIES

  55. Slide 55: Appendix

    Appendix 55

  56. Slide 56: M&A Value Creation Case study: Covance Food Solutions (CFS)

    M&A Value Creation Case study: Covance Food Solutions (CFS) Key highlights Key drivers of value creation • CFS acquired in August 2018 from LabCorp • 12 facilities (9 US, 2 UK, 1 Singapore) • Acquisition rationale: • Significantly strengthened scale and scientific depth of US Food & Feed Testing lab

  57. Slide 57: M&A Value Creation Case study: TestAmerica (TA)

    M&A Value Creation Case study: TestAmerica (TA) Key highlights Key drivers of value creation • TestAmerica acquired in October 2018 from JSTI Group Environment testing and sampling still affected by COVID in 2020 and 2021 • 24 full-service testing laboratories and 40 service centres throughout the U

  58. Slide 58: M&A Value Creation Case study: EAG Materials & Engineering Sciences

    M&A Value Creation Case study: EAG Materials & Engineering Sciences (MS/ES) Key highlights Key drivers of value creation • EAG acquired in September 2017 from Odyssey Investment Partners • Acquisition rationale: • 21 laboratories in 18 locations worldwide • Capabilities in Agroscience testing turned

  59. Slide 59: M&A Value Creation Case study: DiscoverX

    M&A Value Creation Case study: DiscoverX Key highlights Key drivers of value creation • DiscoverX acquired in 2017 • 4 facilities (3 US, 1 UK) • Acquisition rationale: Financial performance • DiscoverX was a leader in drug discovery products and services across all stages of discovery • Eurofins Pha

  60. Slide 60: Definitions / Alternative Performance Measures (APMs)

    Definitions / Alternative Performance Measures (APMs) APMs used in this presentation Adjusted results – reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”. Separately disclosed items (SDI) – include: • one-off costs from integration and reor

Eurofins Scientific — Investor Day (October 2023) on 6ix